Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1524-4733.1998.130167.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bariatric surgery decreases prescription drug costs for metabolic syndrome: a Canadian population-based cohort study.
Surg Endosc
December 2024
Department of Surgery, Max Rady College of Medicine, St. Boniface General Hospital, University of Manitoba, 409 Tache Avenue, Winnipeg, MB, Canada.
Background: Obesity is a chronic disease that is significantly linked to metabolic syndrome. Bariatric surgery is considered the most effective treatment for obesity resulting in long-term weight loss and comorbidity resolution. Prior studies have demonstrated the overall cost effectiveness of bariatric surgery; however, there is little data regarding direct pharmaceutical costs.
View Article and Find Full Text PDFInnovative Applications of Pectin in Lipid Management: Mechanisms, Modifications, Synergies, Nanocarrier Systems, and Safety Considerations.
J Agric Food Chem
September 2024
College of Food Science and Engineering/Collaborative Innovation Center for Modern Grain Circulation and Safety/Key Laboratory of Grains and Oils Quality Control and Processing, Nanjing University of Finance and Economics, Nanjing 210023, China.
Pectin, a natural polysaccharide predominantly sourced from the cell walls of terrestrial plants, is widely regarded for its gelling, thickening, and stabilizing properties, which have extensive applications in the food, pharmaceutical, and biotechnological industries. This review discusses the mechanistic pathways by which pectin mediates its lipid-lowering properties, such as pectin's antioxidant activity, the modulation of gut microbiota, its anti-inflammatory properties, its capacity to bind bile acids and cholesterol, and its impact on the expression of genes associated with lipid metabolism. To enhance its hypolipidemic properties, chemical, physical, and enzymatic modification techniques are explored.
View Article and Find Full Text PDFImpact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis.
Int J Equity Health
June 2024
School of Health Policy and Management, Nanjing Medical University, Nanjing, China.
Background: PCSK9 inhibitors are a novel class of lipid-lowering drugs that have demonstrated favorable efficacy and safety. Evolocumab and alirocumab have been added to China's National Reimbursement Drug List through the National Drug Price Negotiation (NDPN) policy. This study aims to evaluate the impact of the NDPN policy on the utilization and accessibility of these two PCSK9 inhibitors.
View Article and Find Full Text PDFTrends in the Use of Medications for Secondary Ischemic Stroke Prevention in Denmark, 2005-2021.
Neurology
May 2024
From the Departments of Clinical Epidemiology and Clinical Medicine (N.S., K.L., H.T.S.), Aarhus University; Department of Clinical Biochemistry (K.L.), Aarhus University Hospital, Denmark; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine (J.C.L., E.P.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; and Yale School of Medicine (L.H.S.), New Haven, CT.
Background And Objectives: Understanding trends in the use of medications for secondary stroke prevention is crucial for identifying areas for improvement in stroke care. We examined the use of lipid-lowering, antihypertensive, glucose-lowering, oral anticoagulant, and antiplatelet medications after ischemic stroke hospitalization, from 2005 to 2021.
Methods: Using nationwide registries in Denmark, we identified a cohort of patients discharged from hospital with a first-time or recurrent ischemic stroke (N = 150,744).
Patient versus physician preferences for lipid-lowering drug therapy: A discrete choice experiment.
Health Expect
April 2024
Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, China.
Background: The emergence of proprotein convertase subtilisin/kexin type 9 inhibitors offered dyslipidemia patients an alternative to statins for lipid-lowering treatment. Understanding patient and physician preferences for lipid-lowering drugs may promote shared decision-making and improve treatment outcomes.
Methods: This study utilized an online discrete choice experiment (DCE) to assess the relative importance (RI) of six attributes related to lipid-lowering drugs, including frequency of administration, mode of administration, reduction of low-density lipoprotein cholesterol (LDL-C) level, risk of myopathy, risk of liver damage, and out-of-pocket monthly cost.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!